Psychopharmacology

, Volume 212, Issue 4, pp 485–499 | Cite as

Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats

  • Adrie W. Bruijnzeel
  • Mahendra Bishnoi
  • Irma A. van Tuijl
  • Kim F. M. Keijzers
  • Kate R. Yavarovich
  • Tim M. Pasek
  • Jenna Ford
  • Jon C. Alexander
  • Hidetaka Yamada
Original Investigation

Abstract

Rationale

Tobacco withdrawal is characterized by a negative mood state and relatively mild somatic symptoms. Increased noradrenergic transmission has been reported to play an important role in opioid withdrawal, but little is known about the role of noradrenergic transmission in nicotine withdrawal.

Objectives

The aim of these experiments was to investigate the effects of prazosin, clonidine, and propranolol on the negative mood state and somatic signs associated with nicotine withdrawal in rats.

Methods

A discrete-trial intracranial self-stimulation procedure was used to assess the negative affective state of nicotine withdrawal. Elevations in brain reward thresholds are indicative of a deficit in brain reward function.

Results

In all the experiments, the nicotinic acetylcholine receptor antagonist mecamylamine (3 mg/kg) elevated the brain reward thresholds of the nicotine-treated rats and did not affect those of the control rats. The α1-adrenergic receptor antagonist prazosin (0.0625 and 0.125 mg/kg) dose-dependently attenuated the elevations in brain reward thresholds associated with precipitated nicotine withdrawal. The α2-adrenergic receptor agonist clonidine (10–40 μg/kg) and the nonselective β-adrenergic receptor antagonist propranolol (2.5–10 mg/kg) did not attenuate the elevations in brain reward thresholds associated with nicotine withdrawal. Furthermore, mecamylamine (2 mg/kg) induced more somatic signs in the nicotine-treated rats than in the control rats. Clonidine and propranolol, but not prazosin, decreased the total number of somatic signs associated with nicotine withdrawal.

Conclusion

Blockade of α1-adrenergic receptors attenuates the deficit in brain reward function associated with nicotine withdrawal. Antagonism of β-adrenergic receptors or stimulation of α2-adrenergic receptors attenuates the somatic symptoms of nicotine withdrawal.

Keywords

Prazosin Clonidine Propranolol Norepinephrine Adrenergic receptors Nicotine Withdrawal Brain reward function Rats 

Notes

Acknowledgments

This research was funded by a National Institute on Drug Abuse grant (DA023575) and a Flight Attendant Medical Research Institute Young Clinical Scientist Award (Grant nr. 52312) to Adrie Bruijnzeel. Irma van Tuijl received salary support from the Dr. Saal van Zwanenberg Foundation.

References

  1. Ahmed SH, Kenny PJ, Koob GF, Markou A (2002) Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 5:625–626PubMedGoogle Scholar
  2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th ed., text revision edn. American Psychiatric, Washington, DCCrossRefGoogle Scholar
  3. Barr AM, Markou A (2005) Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 29:675–706CrossRefPubMedGoogle Scholar
  4. Bruijnzeel AW, Gold MS (2005) The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Brain Res Rev 49:505–528CrossRefPubMedGoogle Scholar
  5. Bruijnzeel AW, Lewis B, Bajpai LK, Morey TE, Dennis DM, Gold M (2006) Severe deficit in brain reward function associated with fentanyl withdrawal in rats. Biol Psychiatry 59:477–480CrossRefPubMedGoogle Scholar
  6. Bruijnzeel AW, Zislis G, Wilson C, Gold MS (2007) Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32:955–963CrossRefPubMedGoogle Scholar
  7. Bruijnzeel AW, Prado M, Isaac S (2009) Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. Biol Psychiatry 66:110–117CrossRefPubMedGoogle Scholar
  8. Buccafusco JJ, Lapp CA, Westbrooks KL, Ernsberger P (1995) Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 273:1162–1171PubMedGoogle Scholar
  9. Cahill L, Prins B, Weber M, McGaugh JL (1994) Beta-adrenergic activation and memory for emotional events. Nature 371:702–704CrossRefPubMedGoogle Scholar
  10. Carlezon WA Jr (2003) Place conditioning to study drug reward and aversion. Meth Mol Med 84:243–249Google Scholar
  11. Coupar IM (1992) Effect of alpha 2-adrenoceptor agonists on the expression of morphine-withdrawal in rats. Naunyn Schmiedebergs Arch Pharmacol 345:553–557CrossRefPubMedGoogle Scholar
  12. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 168:347–358CrossRefGoogle Scholar
  13. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675–682CrossRefPubMedGoogle Scholar
  14. Debruyne D, Sobrio F, Hinschberger A, Camsonne R, Coquerel A, Barré L (2003) Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J Pharm Sci 92:1051–1057CrossRefPubMedGoogle Scholar
  15. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403:430–434CrossRefPubMedGoogle Scholar
  16. Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 155:52–57CrossRefGoogle Scholar
  17. Eisenach JC, De KM, Klimscha W (1996) alpha(2)-Adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984–1995). Anesthesiology 85:655–674CrossRefPubMedGoogle Scholar
  18. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76–79CrossRefPubMedGoogle Scholar
  19. Ernsberger P, Meeley MP, Mann JJ, Reis DJ (1987) Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134:1–13CrossRefPubMedGoogle Scholar
  20. Fenton HM, Liebman JM (1982) Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. Pharmacol Biochem Behav 17:1207–1212CrossRefPubMedGoogle Scholar
  21. Ferris RM, Maxwell RA, Cooper BR, Soroko FE (1982) Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion. HCl—a new atypical antidepressant agent. Adv Biochem Psychopharmacol 31:277–286PubMedGoogle Scholar
  22. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88–92PubMedGoogle Scholar
  23. Fuentealba JA, Forray MI, Gysling K (2000) Chronic morphine treatment and withdrawal increase extracellular levels of norepinephrine in the rat bed nucleus of the stria terminalis. J Neurochem 75:741–748CrossRefPubMedGoogle Scholar
  24. Garcia-Sevilla JA, Zis AP, Hollingsworth PJ, Greden JF, Smith CB (1981) Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry 38:1327–1333PubMedGoogle Scholar
  25. Georges F, Aston-Jones G (2003) Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors. Neuropsychopharmacology 28:1140–1149PubMedGoogle Scholar
  26. Georges F, Caille S, Vouillac C, Le MC, Stinus L (2005) Role of imidazoline receptors in the anti-aversive properties of clonidine during opiate withdrawal in rats. Eur J Neurosci 22:1812–1816CrossRefPubMedGoogle Scholar
  27. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS (1988) Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 259:2863–2866CrossRefPubMedGoogle Scholar
  28. Gold MS, Redmond DE Jr, Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2:599–602CrossRefPubMedGoogle Scholar
  29. Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev CD000058Google Scholar
  30. Greenwell TN, Walker BM, Cottone P, Zorrilla EP, Koob GF (2009) The alpha1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacol Biochem Behav 91:295–302CrossRefPubMedGoogle Scholar
  31. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683–690CrossRefPubMedGoogle Scholar
  32. Harris GC, Aston-Jones G (1993) Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal. Neuropsychopharmacology 9:303–311PubMedGoogle Scholar
  33. Harrison AA, Liem YT, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25:55–71CrossRefPubMedGoogle Scholar
  34. Honda K, Takenaka T, Shiono K, Miyata-Osawa A, Nakagawa C (1985) Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats. Jpn J Pharmacol 38:31–41CrossRefPubMedGoogle Scholar
  35. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48:52–59PubMedGoogle Scholar
  36. Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031Google Scholar
  37. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337:1195–1202CrossRefPubMedGoogle Scholar
  38. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9(Suppl 1):19–26CrossRefPubMedGoogle Scholar
  39. Irvine EE, Cheeta S, File SE (1999) Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol 10:691–697CrossRefPubMedGoogle Scholar
  40. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691CrossRefPubMedGoogle Scholar
  41. Koob GF (2008) Hedonic homeostatic dysregulation as a driver of drug-seeking behavior. Drug Discov Today Dis Model 5:207–215CrossRefGoogle Scholar
  42. Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the ‘dark side’ of drug addiction. Nat Neurosci 8:1442–1444CrossRefPubMedGoogle Scholar
  43. Koob GF, Caine SB, Parsons L, Markou A, Weiss F (1997) Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 57:513–521CrossRefPubMedGoogle Scholar
  44. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc 38:2473–2476PubMedGoogle Scholar
  45. Kosten TA (1994) Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal. Eur J Pharmacol 254:59–63CrossRefPubMedGoogle Scholar
  46. Liebman JM, Hall N, Prowse J (1982) Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. Pharmacol Biochem Behav 16:785–790CrossRefPubMedGoogle Scholar
  47. Lin Y, de Vaca SC, Carr KD, Stone EA (2007) Role of alpha(1)-adrenoceptors of the locus coeruleus in self-stimulation of the medial forebrain bundle. Neuropsychopharmacology 32:835–841CrossRefPubMedGoogle Scholar
  48. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43:779–784CrossRefPubMedGoogle Scholar
  49. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 115:180–184CrossRefGoogle Scholar
  50. Manion ST, Gamble EH, Li H (2007) Prazosin administered prior to inescapable stressor blocks subsequent exaggeration of acoustic startle response in rats. Pharmacol Biochem Behav 86:559–565CrossRefPubMedGoogle Scholar
  51. Markou A, Koob GF (1991) Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4:17–26PubMedGoogle Scholar
  52. Markou A, Koob GF (1992) Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 51:111–119CrossRefPubMedGoogle Scholar
  53. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 18:135–174CrossRefPubMedGoogle Scholar
  54. McGaugh JL (2000) Memory—a century of consolidation. Science 287:248–251CrossRefPubMedGoogle Scholar
  55. Millan MJ, Rivet JM, Gobert A, Canton H, Veiga S, Bervoets K (1994) 5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm. J Pharmacol Exp Ther 269:121–131PubMedGoogle Scholar
  56. Olds ME, Domino EF (1969) Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. J Pharmacol Exp Ther 166:189–204PubMedGoogle Scholar
  57. Ozdogan UK, Lahdesmaki J, Scheinin M (2003) Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 460:127–134CrossRefPubMedGoogle Scholar
  58. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158:2035–2039CrossRefPubMedGoogle Scholar
  59. Rylkova D, Boissoneault J, Isaac S, Prado M, Shah HP, Bruijnzeel AW (2008) Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides 42:215–227CrossRefPubMedGoogle Scholar
  60. Schulteis G, Markou A, Gold LH, Stinus L, Koob GF (1994) Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose–response analysis. J Pharmacol Exp Ther 271:1391–1398PubMedGoogle Scholar
  61. Schulteis G, Markou A, Cole M, Koob GF (1995) Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92:5880–5884CrossRefPubMedGoogle Scholar
  62. Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology 19:447–454CrossRefPubMedGoogle Scholar
  63. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33–40CrossRefGoogle Scholar
  64. Sparber SB, Meyer DR (1978) Clonidine antagonizes naloxone-induced suppression of conditioned behavior and body weight loss in morphine-dependent rats. Pharmacol Biochem Behav 9:319–325CrossRefPubMedGoogle Scholar
  65. Sugrue MF (1983) Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 21:1–33CrossRefPubMedGoogle Scholar
  66. Timmermans PB, Schoop AM, Kwa HY, Van Zwieten PA (1981) Characterization of alpha-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur J Pharmacol 70:7–15CrossRefPubMedGoogle Scholar
  67. van Stegeren AH, Everaerd W, Cahill L, McGaugh JL, Gooren LJ (1998) Memory for emotional events: differential effects of centrally versus peripherally acting beta-blocking agents. Psychopharmacology (Berl) 138:305–310CrossRefGoogle Scholar
  68. Wagena EJ, Knipschild P, Zeegers MP (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100:317–326CrossRefPubMedGoogle Scholar
  69. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M (2003) Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology (Berl) 170:80–88CrossRefGoogle Scholar
  70. Watkins SS, Stinus L, Koob GF, Markou A (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther 292:1053–1064PubMedGoogle Scholar
  71. Wee S, Mandyam CD, Lekic DM, Koob GF (2008) Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 18:303–311CrossRefPubMedGoogle Scholar
  72. Wing VC, Shoaib M (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) 195:303–313CrossRefGoogle Scholar
  73. Wise RA, Munn E (1995) Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology (Berl) 117:130–136CrossRefGoogle Scholar
  74. Yang XM, Gorman AL, Dunn AJ (1990) The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 255:1064–1070PubMedGoogle Scholar
  75. Zislis G, Desai TV, Prado M, Shah HP, Bruijnzeel AW (2007) Effects of the CRF receptor antagonist D-Phe CRF(12–41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 58:958–966CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Adrie W. Bruijnzeel
    • 1
  • Mahendra Bishnoi
    • 1
  • Irma A. van Tuijl
    • 1
  • Kim F. M. Keijzers
    • 1
  • Kate R. Yavarovich
    • 1
  • Tim M. Pasek
    • 1
  • Jenna Ford
    • 1
  • Jon C. Alexander
    • 1
  • Hidetaka Yamada
    • 1
  1. 1.Department of Psychiatry, McKnight Brain InstituteUniversity of FloridaGainesvilleUSA

Personalised recommendations